PLX5622 NEW
| Price | $97 | $161 | $324 |
| Package | 5mg | 10mg | 25mg |
| Min. Order: | |
| Supply Ability: | 10g |
| Update Time: | 2024-11-18 |
Product Details
| Product Name: PLX5622 | CAS No.: 1303420-67-8 |
| Purity: 99.89% | Supply Ability: 10g |
| Release date: 2024/11/18 |
Product Introduction
Bioactivity
| Name | PLX5622 |
| Description | PLX5622 is a highly selective, brain-penetrant, and orally active CSF1R inhibitor. |
| In vitro | METHODS: CX CR1+/GFP mouse-derived mixed glial cell cultures were treated with PLX5622 (0.1-10 μM) for 7 days and cell counts were assayed by Flow cytometry. RESULTS: Although there was a dose-dependent decrease in microglia numbers under PLX5622, no decrease in GFAP+ astrocytes was seen, but rather a gradual increase, along with a decrease in PDGFR-a OPC. [1] METHODS: Cerebellar sections prepared from PLP-eGFP mouse pups were treated with PLX5622 (1-20 μM) for 3 days followed by Immunostaining. RESULTS: After three days of treatment, PLX5622 at concentrations greater than 2 μM eliminated more than 95% of microglia. [2] |
| In vivo | METHODS: To study in vivo activity, PLX5622 (1200 mg/kg) was administered to PLP eGFP mice by feed for 7-21 days. RESULTS: PLX5622 was effective in depleting microglia in the central nervous system of adult mice. treatment with PLX5622 for 7 days had no effect on oligodendrocyte progenitor cell populations; however, a mild reduction was observed after 21 days in some central nervous system regions. [2] |
| Storage | Powder: -20°C for 3 years | In solvent: -80°C for 1 year | Shipping with blue ice. |
| Solubility Information | DMSO : 16.67 mg/mL (42.15 mM), Sonication is recommended. 10% DMSO+40% PEG300+5% Tween 80+45% Saline : 7.9 mg/mL (19.98 mM), Suspension. Please add co-solvents sequentially, clarifying the solution as much as possible before adding the next one. Dissolve by heating and/or sonication if necessary. Working solution is recommended to be prepared and used immediately. |
| Keywords | Inhibitor | CSF-1 receptor | microglial | PLX 5622 | CSF1R | orally | pathology | inhibit | c-Fms | penetrant | preceding | brain | colony stimulating factor 1 receptor | CSF-1R | elimination | PLX5622 |
| Inhibitors Related | c-Fms-IN-3 | c-Fms-IN-1 | Sotuletinib | Tandutinib | AZD7507 | Pazopanib Hydrochloride | GW2580 | Pexidartinib | c-Fms-IN-13 | Linifanib | Masitinib | Cerdulatinib hydrochloride |
| Related Compound Libraries | 高選擇性抑制劑庫(kù) | 經(jīng)典已知活性庫(kù) | 膜蛋白靶向化合物庫(kù) | 酪氨酸激酶分子庫(kù) | 激酶抑制劑庫(kù) | 藥物功能重定位化合物庫(kù) | 抑制劑庫(kù) | 口服活性化合物庫(kù) | 已知活性化合物庫(kù) | 抗COVID-19化合物庫(kù) |
Company Profile Introduction
Target Molecule Corp. (TargetMol) is a global high-tech enterprise, headquartered in Boston, MA, specializing in chemical and biological research product and service to meet the research needs of global customers.
TargetMol has evolved into one of the biggest global compound library and small molecule suppliers and a customer based on 40+ countries. TargetMol offers over 80 types of compound libraries and a wide range of high-quality research chemicals including inhibitors, activator, natural compounds, peptides, inhibitory antibodies, and novel life-science kits, for laboratory and scientific use. Besides, virtual screening service is also available for customers who would like to conduct the computer-aided drug discovery.
You may like
Recommended supplier
| Product name | Price | Suppliers | Update time | |
|---|---|---|---|---|
| $150.00/1KG |
VIP2Y
|
Zibo Hangyu Biotechnology Development Co., Ltd
|
2023-10-07 | |
| $2900.00/10g |
Shanghai Qianyi New Material Co., Ltd.
|
2023-05-22 | ||
| $1.10/1g |
VIP4Y
|
Dideu Industries Group Limited
|
2021-08-17 |
United States- Since: 2011-01-07
- Address: 36?Washington?Street, Wellesley?Hills
INQUIRY